Telemonitoring Platform "CUREETY TECHCARE" vs Standard of Care for mTBNC Patients Initiati
The goal of this clinical trial is to assess whether adding telemonitoring (the digital telemonitoring platform "CUREETY TECHCARE"), to standard care, will benefit patients with previously untreated metastatic triple-negative breast cancer starting first-line cancer therapy. The main questions it aims to answer are: *
| Condition(s) | Metastatic Triple-Negative Breast Carcinoma |
|---|---|
| Status | Recruiting |
| Phase | NA |
| Study type | Interventional |
| Summary | The goal of this clinical trial is to assess whether adding telemonitoring (the digital telemonitoring platform "CUREETY TECHCARE"), to standard care, will benefit patients with previously untreated metastatic triple-negative breast cancer starting first-line cancer therapy. The main questions it aims to answer are: * Is patient quality of life improved by using the telemonitoring platform? * Are patients hospitalized less frequently when using the telemonitoring platform? * Is the patient overall survival improved by telemonitoring ? Researchers will compare data from patients using telemonitoring while receiving standard care with data from patients receiving only standard care. Participants using telemonitoring will answer questions about their symptoms on the platform. The platform wil |
| Who can participate | Inclusion Criteria: * Signed a written informed consent form prior to participate in the study. Note: In case of physical incapacitation, a trusted representative of their choice, which is not the Investigator or sponsor, can sign on the behalf of the patients * Patients ≥18 years of age. * Patient with histologically documented metastatic triple negative breast cancer (ER (Oestrogen receptor) and PR (Progesterone receptor) \<10%, Her2 negative status). * Life expectancy \> 6 months as per investigator estimate. * Patient initiating a marketed authorized first-line systemic treatment in the metastatic setting. * Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≤2. * Patient having completed the EORTC QLQ-C30 and EORTC QLQ-BR45 at baseline (response to questions 29 and 30 o |
| Ages | 18 Years |
| Sex | All |
| Lead sponsor | UNICANCER |
| Locations | Arras, France; Auxerre, France; Avignon, France; Bayeux, France; Beauvais, France; Beuvry, France (+45 more sites) |
| Start date | 2024-07-25 |
| NCT ID | NCT06505018 |
| Official listing | https://clinicaltrials.gov/study/NCT06505018 |